Compounds > 2-(5-butoxy-1-oxo-2-isoquinolinyl)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)acetamide
Page last updated: 2024-11-13

2-(5-butoxy-1-oxo-2-isoquinolinyl)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)acetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID23640021
CHEMBL ID260419
CHEBI ID93329

Synonyms (16)

Synonym
bdbm28655
isoquinolinone scaffold, 14
cid_23640021
2-(5-butoxy-1-oxo-1,2-dihydroisoquinolin-2-yl)-n-(2,3-dihydro-1,4-benzodioxin-6-yl)acetamide
ml018
SR-03000000057-1
CHEMBL260419
MLS002474513
smr001398685
CHEBI:93329
2-(5-butoxy-1-oxo-2-isoquinolinyl)-n-(2,3-dihydro-1,4-benzodioxin-6-yl)acetamide
Q27165042
5-butoxy-n-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-oxo-2(1h)-isoquinolineacetamide
DTXSID701136358
1014107-46-0
2-(5-butoxy-1-oxoisoquinolin-2-yl)-n-(2,3-dihydro-1,4-benzodioxin-6-yl)acetamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Smad3Homo sapiens (human)Potency25.11890.00527.809829.0929AID588855
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor ROR-alphaHomo sapiens (human)IC50 (µMol)21.50000.19951.59982.6000AID329655
Steroidogenic factor 1Homo sapiens (human)IC50 (µMol)13.70000.03001.69807.3000AID329653
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Steroidogenic factor 1Homo sapiens (human)EC50 (µMol)13.70000.20000.48000.7600AID1798910
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (46)

Processvia Protein(s)Taxonomy
positive regulation of transcription by RNA polymerase IINuclear receptor ROR-alphaHomo sapiens (human)
angiogenesisNuclear receptor ROR-alphaHomo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor ROR-alphaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-alphaHomo sapiens (human)
nitric oxide biosynthetic processNuclear receptor ROR-alphaHomo sapiens (human)
regulation of smoothened signaling pathwayNuclear receptor ROR-alphaHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionNuclear receptor ROR-alphaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-alphaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-alphaHomo sapiens (human)
cerebellar Purkinje cell differentiationNuclear receptor ROR-alphaHomo sapiens (human)
cerebellar granule cell precursor proliferationNuclear receptor ROR-alphaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-alphaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-alphaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-alphaHomo sapiens (human)
cholesterol homeostasisNuclear receptor ROR-alphaHomo sapiens (human)
muscle cell differentiationNuclear receptor ROR-alphaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-alphaHomo sapiens (human)
regulation of macrophage activationNuclear receptor ROR-alphaHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionNuclear receptor ROR-alphaHomo sapiens (human)
negative regulation of fat cell differentiationNuclear receptor ROR-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-alphaHomo sapiens (human)
cGMP metabolic processNuclear receptor ROR-alphaHomo sapiens (human)
negative regulation of inflammatory responseNuclear receptor ROR-alphaHomo sapiens (human)
triglyceride homeostasisNuclear receptor ROR-alphaHomo sapiens (human)
cellular response to interleukin-1Nuclear receptor ROR-alphaHomo sapiens (human)
cellular response to tumor necrosis factorNuclear receptor ROR-alphaHomo sapiens (human)
cellular response to hypoxiaNuclear receptor ROR-alphaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-alphaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-alphaHomo sapiens (human)
luteinizationSteroidogenic factor 1Homo sapiens (human)
sex determinationSteroidogenic factor 1Homo sapiens (human)
primary sex determinationSteroidogenic factor 1Homo sapiens (human)
male gonad developmentSteroidogenic factor 1Homo sapiens (human)
female gonad developmentSteroidogenic factor 1Homo sapiens (human)
positive regulation of gene expressionSteroidogenic factor 1Homo sapiens (human)
male sex determinationSteroidogenic factor 1Homo sapiens (human)
adrenal gland developmentSteroidogenic factor 1Homo sapiens (human)
intracellular receptor signaling pathwaySteroidogenic factor 1Homo sapiens (human)
Leydig cell differentiationSteroidogenic factor 1Homo sapiens (human)
hormone metabolic processSteroidogenic factor 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISteroidogenic factor 1Homo sapiens (human)
regulation of steroid biosynthetic processSteroidogenic factor 1Homo sapiens (human)
maintenance of protein location in nucleusSteroidogenic factor 1Homo sapiens (human)
Sertoli cell differentiationSteroidogenic factor 1Homo sapiens (human)
positive regulation of male gonad developmentSteroidogenic factor 1Homo sapiens (human)
negative regulation of female gonad developmentSteroidogenic factor 1Homo sapiens (human)
regulation of transcription by RNA polymerase IISteroidogenic factor 1Homo sapiens (human)
tissue developmentSteroidogenic factor 1Homo sapiens (human)
hormone-mediated signaling pathwaySteroidogenic factor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (19)

Processvia Protein(s)Taxonomy
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor ROR-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-alphaHomo sapiens (human)
transcription coregulator bindingNuclear receptor ROR-alphaHomo sapiens (human)
transcription corepressor bindingNuclear receptor ROR-alphaHomo sapiens (human)
transcription coactivator bindingNuclear receptor ROR-alphaHomo sapiens (human)
DNA bindingNuclear receptor ROR-alphaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-alphaHomo sapiens (human)
protein bindingNuclear receptor ROR-alphaHomo sapiens (human)
beta-catenin bindingNuclear receptor ROR-alphaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-alphaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-alphaHomo sapiens (human)
sequence-specific DNA bindingNuclear receptor ROR-alphaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-alphaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingSteroidogenic factor 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingSteroidogenic factor 1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificSteroidogenic factor 1Homo sapiens (human)
transcription coregulator bindingSteroidogenic factor 1Homo sapiens (human)
DNA bindingSteroidogenic factor 1Homo sapiens (human)
chromatin bindingSteroidogenic factor 1Homo sapiens (human)
nuclear receptor activitySteroidogenic factor 1Homo sapiens (human)
protein bindingSteroidogenic factor 1Homo sapiens (human)
phospholipid bindingSteroidogenic factor 1Homo sapiens (human)
zinc ion bindingSteroidogenic factor 1Homo sapiens (human)
enzyme bindingSteroidogenic factor 1Homo sapiens (human)
sequence-specific DNA bindingSteroidogenic factor 1Homo sapiens (human)
sequence-specific double-stranded DNA bindingSteroidogenic factor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
nucleusNuclear receptor ROR-alphaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-alphaHomo sapiens (human)
nucleolusNuclear receptor ROR-alphaHomo sapiens (human)
chromatinNuclear receptor ROR-alphaHomo sapiens (human)
nucleusNuclear receptor ROR-alphaHomo sapiens (human)
nucleusSteroidogenic factor 1Homo sapiens (human)
nucleoplasmSteroidogenic factor 1Homo sapiens (human)
cytosolSteroidogenic factor 1Homo sapiens (human)
chromatinSteroidogenic factor 1Homo sapiens (human)
RNA polymerase II transcription regulator complexSteroidogenic factor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1798910Transactivation Cell-Based Assay from Article 10.1016/j.bmcl.2008.03.027: \\Synthesis of small molecule inhibitors of the orphan nuclear receptor steroidogenic factor-1 (NR5A1) based on isoquinolinone scaffolds.\\2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis of small molecule inhibitors of the orphan nuclear receptor steroidogenic factor-1 (NR5A1) based on isoquinolinone scaffolds.
AID329653Inhibition of GAL4-tagged NR5A1 by luciferase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis of small molecule inhibitors of the orphan nuclear receptor steroidogenic factor-1 (NR5A1) based on isoquinolinone scaffolds.
AID329657Inhibition of HSV1 GAL4-tagged VP16 by luciferase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis of small molecule inhibitors of the orphan nuclear receptor steroidogenic factor-1 (NR5A1) based on isoquinolinone scaffolds.
AID329655Inhibition of GAL4-tagged RORalpha by luciferase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis of small molecule inhibitors of the orphan nuclear receptor steroidogenic factor-1 (NR5A1) based on isoquinolinone scaffolds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
2-[[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxo-5-isoquinolinyl]oxy]propanoic acid ethyl ester
[no description available]		2.0410isoquinolines
2-[[2-[2-(4-methoxyanilino)-2-oxoethyl]-1-oxo-5-isoquinolinyl]oxy]propanoic acid ethyl ester
[no description available]		2.0410isoquinolines
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510